.png){kind=icon}
.png){kind=icon}
Return
Faricimab for High-Need Aflibercept 2 mg Treated Neovascular Age-Related Macular Degeneration
.png){kind=icon}
PRE
AI
M
R
S
L
F
D
A
A
M
DOI：10.1016/j.oret.2026.07.009.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To assess whether “high-need” treated neovascular age-related macular degeneration (nAMD) eyes, requiring aflibercept 2 mg every 3-5 weeks, can be extended in their treatment interval when switched to faricimab.
Keywords:
Neovascular age-related macular degeneration
faricimab
aflibercept 2 mg
switch
treatment resistant
Ang-2
Angiopoietin-2
AMD
age-related macular degeneration
BCVA
best-corrected visual acuity
CI
confidence interval
CST
central subfield thickness
ETDRS
Early Treatment Diabetic Retinopathy Study
IRF
intraretinal fluid
IOI
intraocular inflammation
ITT
intention-to-treat
LSMD
least square mean difference
nAMD
neovascular age-related macular degeneration
OCT
Optical Coherence Tomography
RCT
randomized clinical trial
SAE
serious adverse event
SRF
subretinal fluid
SD-OCT
Spectral Domain Optical Coherence Tomography
TandE
treat-and-extend
VEGF
Vascular Endothelial Growth Factor
Journal
IF:
5.7
Papers:
584
Citations:
4.1K
Organization
Cited Papers